24 related articles for article (PubMed ID: 21365630)
1. Unintended consequences of decreased PSA-based prostate cancer screening.
Ahlering T; Huynh LM; Kaler KS; Williams S; Osann K; Joseph J; Lee D; Davis JW; Abaza R; Kaouk J; Patel V; Kim IY; Porter J; Hu JC
World J Urol; 2019 Mar; 37(3):489-496. PubMed ID: 30003374
[TBL] [Abstract][Full Text] [Related]
2. Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy.
Karnes RJ; Sharma V; Choeurng V; Ashab HA; Erho N; Alshalalfa M; Trock B; Ross A; Yousefi K; Tsai H; Zhao SG; Tosoian JJ; Haddad Z; Takhar M; Chang SL; Spratt DE; Abdollah F; Jenkins RB; Klein EA; Nguyen PL; Dicker AP; Den RB; Davicioni E; Feng FY; Lotan TL; Schaeffer EM
Clin Cancer Res; 2018 Aug; 24(16):3908-3916. PubMed ID: 29760221
[No Abstract] [Full Text] [Related]
3. Comparative Effectiveness of Cancer Control and Survival after Robot-Assisted versus Open Radical Prostatectomy.
Hu JC; O'Malley P; Chughtai B; Isaacs A; Mao J; Wright JD; Hershman D; Sedrakyan A
J Urol; 2017 Jan; 197(1):115-121. PubMed ID: 27720782
[TBL] [Abstract][Full Text] [Related]
4. The diffusion of minimally invasive radical prostatectomy in the United States: a case study of the introduction of new surgical devices.
Anderson CB; Elkin EB; Atoria CL; Eastham JA; Scardino PT; Touijer K
Prostate Cancer Prostatic Dis; 2015 Mar; 18(1):75-80. PubMed ID: 25512262
[TBL] [Abstract][Full Text] [Related]
5. Understanding regional variation in Medicare expenditures for initial episodes of prostate cancer care.
Wang SY; Wang R; Yu JB; Ma X; Xu X; Kim SP; Soulos PR; Saraf A; Gross CP
Med Care; 2014 Aug; 52(8):680-7. PubMed ID: 25023913
[TBL] [Abstract][Full Text] [Related]
6. Low rates of adjuvant radiation in patients with nonmetastatic prostate cancer with high-risk pathologic features.
Kalbasi A; Swisher-McClure S; Mitra N; Sunderland R; Smaldone MC; Uzzo RG; Bekelman JE
Cancer; 2014 Oct; 120(19):3089-96. PubMed ID: 24917426
[TBL] [Abstract][Full Text] [Related]
7. Comparison of SEER Treatment Data With Medicare Claims.
Noone AM; Lund JL; Mariotto A; Cronin K; McNeel T; Deapen D; Warren JL
Med Care; 2016 Sep; 54(9):e55-64. PubMed ID: 24638121
[TBL] [Abstract][Full Text] [Related]
8. A systematic review of the volume-outcome relationship for radical prostatectomy.
Trinh QD; Bjartell A; Freedland SJ; Hollenbeck BK; Hu JC; Shariat SF; Sun M; Vickers AJ
Eur Urol; 2013 Nov; 64(5):786-98. PubMed ID: 23664423
[TBL] [Abstract][Full Text] [Related]
9. Beyond castration-defining future directions in the hormonal treatment of prostate cancer.
Niraula S; Chi K; Joshua AM
Horm Cancer; 2012 Apr; 3(1-2):3-13. PubMed ID: 22124843
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer: What is the cost of modern cancer treatment?
Fenner A
Nat Rev Urol; 2011 Jun; 8(7):354. PubMed ID: 21670753
[No Abstract] [Full Text] [Related]
11. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
12. Radical prostatectomy for clinical T4 prostate cancer.
Johnstone PA; Ward KC; Goodman M; Assikis V; Petros JA
Cancer; 2006 Jun; 106(12):2603-9. PubMed ID: 16700037
[TBL] [Abstract][Full Text] [Related]
13. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy.
Kamat AM; Babaian K; Cheung MR; Naya Y; Huang SH; Kuban D; Babaian RJ
J Urol; 2003 Nov; 170(5):1860-3. PubMed ID: 14532793
[TBL] [Abstract][Full Text] [Related]
14. Utilization and expense of adjuvant cancer therapies following radical prostatectomy.
Williams SB; Gu X; Lipsitz SR; Nguyen PL; Choueiri TK; Hu JC
Cancer; 2011 Nov; 117(21):4846-54. PubMed ID: 21365630
[TBL] [Abstract][Full Text] [Related]
15. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
16. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
